Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 12/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911895 | 0.91 | DUT (0.59) | DUTL3MBTL1ALDH1A1LMNAPKM | |
| SCHEMBL913379 | 0.91 | DUT (0.59) | DUTL3MBTL1ALDH1A1LMNAPKM | |
| SCHEMBL11498513 | 0.85 | DUT (0.53) | DUTL3MBTL1ALDH1A1LMNAPKM | |
| SCHEMBL11498514 | 0.85 | DUT (0.53) | DUTL3MBTL1ALDH1A1LMNAPKM | |
| SCHEMBL13999365 | 0.84 | DUT (0.53) | DUTL3MBTL1ALDH1A1LMNAPKM | |
| SCHEMBL21099930 | 0.81 | DUT (0.50) | DUTL3MBTL1ALDH1A1LMNAPKM | |
| SCHEMBL26916340 | 0.81 | L3MBTL1 (0.50) | DUTL3MBTL1ALDH1A1LMNAPKM | |
| SCHEMBL911948 | 0.81 | DUT (0.72) | DUT | |
| SCHEMBL11474759 | 0.81 | DUT (0.49) | DUTL3MBTL1ALDH1A1LMNAPKM | |
| SCHEMBL2983407 | 0.80 | ALDH1A1 (0.57) | DUTL3MBTL1ALDH1A1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2322534-A1 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2011-05-18 | — | — | EP | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-20040242533-A1 | Antiviral nucleosides | KUMAR, RAKESH (CA) | 2004-12-02 | — | — | US | disclosed |
| EP-1387850-A2 | ANTIVIRAL NUCLEOSIDES | Kumar, Rakesh (CA) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002094844-A2 | ANTIVIRAL NUCLEOSIDES | KUMAR RAKESH (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242533-A1 | Antiviral nucleosides | ENTPD5, DUT, ADA | DUT 2/4885L3MBTL1 1697/4885ALDH1A1 1901/4885 |
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | DUT 1/4885L3MBTL1 392/4885ALDH1A1 1723/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | DUT 1/4885L3MBTL1 344/4885ALDH1A1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.